<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644471</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190061</org_study_id>
    <secondary_id>2019-A02078-49</secondary_id>
    <nct_id>NCT04644471</nct_id>
  </id_info>
  <brief_title>Comparison Between Ultra-low-dose Computed Tomography and Lung MRI in Cystic Fibrosis</brief_title>
  <acronym>UBD-IRM</acronym>
  <official_title>Comparison Between Ultra-low-dose Computed Tomography and Lung MRI for Morphological Assessment of Lung Disease in Adult Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the performances of ultra-low dose computed&#xD;
      tomography (CT) and lung magnetic resonance imaging (MRI) for morphological assessment of&#xD;
      cystic fibrosis-related lung disease and to compare their performances to conventional low&#xD;
      dose CT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is a recessive autosomal disease caused by mutations in the cystic&#xD;
      fibrosis transmembrane conductance regulator (CFTR) gene that encodes for an epithelial&#xD;
      chloride channel involved in ion and fluid transport. CF is the most common inherited disease&#xD;
      in Caucasians and disease severity mainly depends on the degree of lung involvement, which&#xD;
      can lead to terminal respiratory failure Disease monitoring of CF-related lung disease rely&#xD;
      on functional assessment and complimentary morphological assessment. Conventional low-dose&#xD;
      chest computed tomography (CT) is currently the gold standard for the morphological&#xD;
      assessment of CF-related lung disease but ultra-low dose chest CT and high-resolution&#xD;
      magnetic resonance imaging (MRI) of the lung using UTE sequences have been recently developed&#xD;
      and allow important radiation reduction of radiation dose exposure. However the performances&#xD;
      of these 2 competing imaging methods remains to be compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reproducibility of visual score between imaging modalities</measure>
    <time_frame>1 day</time_frame>
    <description>Reproducibility disease severity measured by the Helbich scoring system with conventional CT as gold standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra and interobserver reproducibility of visual scores</measure>
    <time_frame>1 day</time_frame>
    <description>Intra and interobserver reproducibility of the Helbich score for each imaging modality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between visual scores and pulmonary function</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation between the Helbich score for each imaging modality and forced expiratory volume in 1 second (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between air trapping at MRI and pulmonary function test</measure>
    <time_frame>1 day</time_frame>
    <description>Correlation between air trapping, measured by comparing inspiratory to expiratory MRI images, and forced expiratory volume at one second (FEV1)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT scanner</intervention_name>
    <description>1 conventional low dose inspiratory acquisition and 1 ultra-low-dose inspiratory acquisition</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lung MRI</intervention_name>
    <description>3 UTE sequences (free breathing, inspiratory and expiratory) and 1 T2 sequence</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 year-old&#xD;
&#xD;
          -  Diagnosis of cystic fibrosis provided by genetic and swear test&#xD;
&#xD;
          -  Chest CT acquisition performed as part of the standard follow-up&#xD;
&#xD;
          -  Patient with social security or health insurance&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI contraindication&#xD;
&#xD;
          -  Pulmonary exacerbation requiring intravenous antibiotics in the previous 30 days&#xD;
&#xD;
          -  Orthopnea&#xD;
&#xD;
          -  Inability to hold breath for 17 seconds&#xD;
&#xD;
          -  No pulmonary function tests planned the same day as imaging procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Pierre REVEL, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume CHASSAGNON, PhD</last_name>
    <phone>+33 1 58 41 53 66</phone>
    <email>guillaume.chassagnon@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adèle BELLINO</last_name>
    <phone>+33 158411195</phone>
    <email>adele.bellino@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cochin hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CHASSAGNON, PhD</last_name>
      <phone>+33 1 58 41 53 66</phone>
      <email>guillaume.chassagnon@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Adèle BELLINO</last_name>
      <phone>+ 33 158411195</phone>
      <email>adele.bellino@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dournes G, Grodzki D, Macey J, Girodet PO, Fayon M, Chateil JF, Montaudon M, Berger P, Laurent F. Quiet Submillimeter MR Imaging of the Lung Is Feasible with a PETRA Sequence at 1.5 T. Radiology. 2015 Jul;276(1):258-65. doi: 10.1148/radiol.15141655. Epub 2015 Mar 13. Erratum in: Radiology. 2016 Apr;279(1):328.</citation>
    <PMID>25768672</PMID>
  </reference>
  <reference>
    <citation>Dournes G, Menut F, Macey J, Fayon M, Chateil JF, Salel M, Corneloup O, Montaudon M, Berger P, Laurent F. Lung morphology assessment of cystic fibrosis using MRI with ultra-short echo time at submillimeter spatial resolution. Eur Radiol. 2016 Nov;26(11):3811-3820. Epub 2016 Feb 2.</citation>
    <PMID>26843010</PMID>
  </reference>
  <reference>
    <citation>Chassagnon G, Martin C, Ben Hassen W, Freche G, Bennani S, Morel B, Revel MP. High-resolution lung MRI with Ultrashort-TE: 1.5 or 3 Tesla? Magn Reson Imaging. 2019 Sep;61:97-103. doi: 10.1016/j.mri.2019.04.015. Epub 2019 Apr 30.</citation>
    <PMID>31051201</PMID>
  </reference>
  <reference>
    <citation>Chassagnon G, Martin C, Marini R, Vakalopolou M, Régent A, Mouthon L, Paragios N, Revel MP. Use of Elastic Registration in Pulmonary MRI for the Assessment of Pulmonary Fibrosis in Patients with Systemic Sclerosis. Radiology. 2019 May;291(2):487-492. doi: 10.1148/radiol.2019182099. Epub 2019 Mar 5.</citation>
    <PMID>30835186</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Multidetector computed tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

